华东医药 reported revenue of ¥22.07B for the period ended 2026-06-30, +1.8% year on year. Net income was ¥1.84B, a 8.3% net margin on a 32.8% gross margin. The largest revenue line is 商业 at 69% of the total. Free cash flow for the period was ¥2.90B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥22.07B | +1.8% |
| Gross profit | ¥7.24B | — |
| Operating income | ¥2.26B | — |
| Net income | ¥1.84B | +2.0% |
| Gross margin | 32.8% | Net margin 8.3% |
| Revenue Q/Q | -2.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 商业 | ¥15.22B | 69.0% |
| 制造业 | ¥7.73B | 35.0% |
| 医美 | ¥0.52B | 2.4% |
| 其他(补充) | ¥0.21B | 0.9% |
| 分部间抵销 | ¥-1.61B | -7.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥14.83B | 67.2% |
| R&D | ¥0.75B | 3.4% |
| SG&A | ¥4.11B | 18.6% |
| Tax & other | ¥0.42B | 1.9% |
| Item | Amount |
|---|---|
| Total assets | ¥39.98B |
| Total liabilities | ¥14.20B |
| Shareholders' equity | ¥25.78B |
| Equity / assets | 64.5% |
| Operating cash flow | ¥3.35B |
| Capital expenditure | ¥0.46B |
| Free cash flow | ¥2.90B |
| Cash conversion (OCF / net income) | 136% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
山金国际 ・ 浪潮信息 ・ 华工科技 ・ 华润三九 ・ 中国铀业 ・ 国货航 ・ 招商公路 ・ 招商蛇口 ・ 新和成 ・ 分众传媒 ・ 思源电气 ・ 紫光国微
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies